Standout Papers

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Ri... 2020 2026 2022 2024242
  1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (2020)
    Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology

Immediate Impact

53 standout
Sub-graph 1 of 20

Citing Papers

Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
2025 Standout
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
7 intermediate papers

Works of Polina Kaplan being referenced

ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
2020 Standout
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
2019
and 1 more

Author Peers

Author Last Decade Papers Cites
Polina Kaplan 272 220 111 9 319
Laurie Musial 263 218 133 8 345
Rose Mantel 244 185 96 13 317
M. Lenoci 202 180 106 10 347
Viralkumar Patel 180 116 60 11 347
Talha Munir 308 252 95 14 340
Binsah George 250 187 99 8 284
Francesca Yates 254 200 92 10 272
Adam Albitar 230 185 51 8 269
E Moreau 241 218 32 7 310
Abigail S. Kelliher 173 157 132 9 361

All Works

Loading papers...

Rankless by CCL
2026